Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evolus, Inc.    EOLS

EVOLUS, INC.

(EOLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Historically, the company has been releasing figures that are above expectations.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Technically, the stock approaches a strong medium-term resistance at USD 5.83.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
EVOLUS, INC.72.32%195
GILEAD SCIENCES, INC.16.70%85 227
VERTEX PHARMACEUTICALS0.15%61 551
WUXI APPTEC CO., LTD.14.44%58 153
REGENERON PHARMACEUTICALS12.25%57 234
BEIGENE, LTD.40.41%33 081
GENMAB A/S8.65%28 472
BIONTECH SE26.63%24 856
HUALAN BIOLOGICAL ENGINEERI..17.76%14 035
ARGENX SE-0.99%13 723
MYOKARDIA, INC.0.00%11 993
-
MIRATI THERAPEUTICS, INC.-3.11%10 700
NEUROCRINE BIOSCIENCES, INC..13.49%10 378
FATE THERAPEUTICS, INC.19.88%9 992
DENALI THERAPEUTICS INC.-7.46%9 295
ULTRAGENYX PHARMACEUTICAL I..-2.37%8 941
More Results
Financials (USD)
Sales 2020 58,0 M - -
Net income 2020 -65,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,97x
Yield 2020 -
Capitalization 195 M 195 M -
Capi. / Sales 2020 3,37x
Capi. / Sales 2021 2,22x
Nbr of Employees 125
Free-Float 66,0%
Upcoming event on EVOLUS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes